EICHORCondition: Crohn's Disease · Sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study employs a multicenter, randomized, double-blind, placebo-controlled, parallel-group, continuous treatment design to evaluate the efficacy, safety, PPK characteristics, and PD effects of H021 Enteric-coated Tablets during both the induction and maintenance treatment periods in patients with moderately to severely active CD. This study consists of an up to 4-week screening period, a 12-week double-blind induction treatment period, a 40-week double-blind maintenance treatment period or open-label extension treatment period, and a 4-week safety follow-up period.
This description comes directly from the study's public registry record.
zhengyu song · +8617714378726 · songzhengyu@carephar.com
Always discuss trial participation with your own doctor first.
| Medical Research Center of Connecticut | Hamden, Connecticut, United States | — |
| Alliance Medical Research - Lighthouse Point | Lighthouse PT, Florida, United States | — |
| AdventHealth Medical Group Inflammatory Bowel Disease Clinic at Orlando | Orlando, Florida, United States | — |
| Peking University First Hospital | Beijing, China | — |
| The First Affiliated Hospital of Bengbu Medical University | Bengbu, China | — |
| The Second Xiangya Hospital of Central South University | Changsha, China | — |
| Xiangya Hospital of Central South University | Changsha, China | — |
| Chongqing General Hospital | Chongqing, China | — |
| The First Affiliated Hospital of Fujian Medical University | Fujian, China | — |
| The First Hospital of Quanzhou, Fujian Medical University | Fujian, China | — |
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, China | — |
| Zhujiang Hospital of Southern Medical University | Guangzhou, China | — |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07677514